NEWS
LATEST
FULL LIST
-
VivoSim Labs Introduces NAMkind Platform for Human-Based Drug Testing Models
VivoSim Labs, a new initiative associated with Organovo, has launched a suite of services under the brand “NAMkind,” aimed at improving drug development through human-based predictive models. The company focuses on New Approach Methodologies (NAMs), which include both engineered human tissue systems and in silico modeling, to offer alternatives to traditional animal testing. VivoSim develops…
-
Cellino and Karis Bio Partner to Advance Personalized iPSC Therapies for Peripheral Artery Disease
Cellino, a Cambridge-based biotech innovator specializing in autonomous biomanufacturing, has announced a strategic partnership with Karis Bio, a South Korean leader in cell therapy, to drive forward a groundbreaking autologous induced pluripotent stem cell (iPSC)-derived therapy for cardiovascular disease. This collaboration not only marks Cellino’s expansion into the Asia-Pacific market but also represents a pivotal…
-
Vivodyne CEO Discusses FDA’s Move Away from Animal Testing and the Future of Humanized Drug Development
By Contract Pharma Staff Vivodyne, a pioneering biotech developing humanized drug testing platforms, stands positioned to capitalize as the FDA announces its initiative to phase out animal testing requirements for monoclonal antibodies (mAbs) and other drug therapies. With its fully automated platform that uses lab-grown human tissues and AI-driven analysis, Vivodyne is ready to push…
-
Organovo Rebrands as VivoSim Labs to Advance 3D Bioprinting Technology
Organovo Holdings, Inc. (Nasdaq: ONVO), a pioneer in 3D bioprinting technology, announced today that it will officially change its name to VivoSim Labs, Inc., marking a new chapter in the company’s mission to advance bioprinting innovations. The rebranding takes effect on April 24, 2025, when the company will begin trading under the new ticker symbol…
-
Cellbricks Reports Preclinical Success with Bioprinted Tissue in Mice
German startup Cellbricks Therapeutics, a spin-off of the Technical University of Berlin, has announced successful preclinical results for its 3D-bioprinted adipose tissue implants. In a study conducted on mice, the company reported full integration of the implants into host tissue after seven weeks, without signs of fibrosis or rejection. Milestone in Animal Testing According to…
-
FluidForm Bio Launches $1.24M Crowdfunding Round to Advance Bioprinted Diabetes Therapy
FluidForm Bio, a regenerative medicine company developing 3D bioprinted cell therapies for diabetes, has launched a new fundraising campaign on StartEngine, aiming to raise up to $1.24 million through a convertible note offering. The Waltham-based company is pursuing a novel approach to treating type 1 diabetes using its proprietary FRESH™ (Freeform Reversible Embedding of Suspended…
-
Xylyx Bio Secures $1.125 Million to Advance Innovations in Xenogeneic Cross-Circulation Transplant Organs
Xylyx Bio, Inc., a regenerative medicine company, today announced that it has received $1,000,000 from the Richard M. Bartlett Jr. Memorial Foundation and an additional $125,000 from the Ilene Beal Foundation and Margaret Stewart Lindsay Foundation. These funds will accelerate the translational development of Xylyx’s groundbreaking bioengineered human lung grafts, which aim to drastically increase…
-
Organovo Sells FXR Drug Program to Eli Lilly in Strategic Deal to Advance IBD Therapies
Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical-stage biotechnology company pioneering 3D tissue-based drug discovery, announced today the successful completion of the sale of its FXR program—including lead therapeutic candidate FXR314—to Eli Lilly and Company (NYSE: LLY). The transaction, finalized on March 25, 2025, grants Lilly all commercial and intellectual property rights associated with Organovo’s FXR…
-
LyGenesis Receives Green Light to Advance Organ Regeneration Trial
LyGenesis, a clinical-stage biotech company pioneering a bold new approach to organ regeneration, has just hit an important milestone in its clinical trial for treating end-stage liver disease (ESLD). The company announced that an independent Data and Safety Monitoring Board (DSMB) has approved the continuation and dose escalation of its ongoing Phase 2a clinical trial.…
-
How Cellino and Matricelf are Advancing Neural Tissue Engineering
Introduction Cellino and Matricelf have announced a global collaboration aimed at advancing personalized treatments for spinal cord injuries. The partnership brings together innovative biomanufacturing and regenerative techniques to develop scalable, patient-specific therapies. Partnership Overview The collaboration leverages Cellino’s Nebula™ technology—an automated, closed-cassette system for producing high-quality induced pluripotent stem cells (iPSCs)—and Matricelf’s proprietary double autologous…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 